Daniel H. Lins-Silva

2 papers in the library · 46 citations · publishing 2022-2025

Papers

Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review

Harvard Review of Psychiatry March 1, 2022 Igor D. Bandeira, Daniel H. Lins-Silva, Vitor Breseghello Cavenaghi et al. 35 citations

Ketamine shows potential for fast onset of action and good tolerability in treating obsessive-compulsive disorder (OCD), but results have been erratic. The systematic review included nine articles: three randomized controlled trials, three case reports, two open-label trials, and one retrospective chart review. Most studies used only single-session racemic ketamine administered intravenously. No evidence demonstrates whether racemic ketamine, S-ketamine, or R-ketamine has the best efficacy, and only sparse evidence suggests combining ketamine with psychotherapy could benefit patients. Future randomized, double-blind, placebo-controlled trials with larger samples, multiple sessions, and appropriate washout periods are needed.

DOI: 10.1097/hrp.0000000000000330 Ketamine Tolerability Randomized controlled trial Placebo +13

Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine or esketamine in treatment-resistant depression? A secondary analysis from a randomized controlled trial

Trends in Psychiatry and Psychotherapy May 27, 2025 Mariana V. F. Echegaray, Rodrigo P. Mello, Guilherme M. Magnavita et al. 11 citations

Among people with treatment-resistant depression, the intensity of dissociation caused by a single infusion of ketamine or esketamine is linked to greater antidepressant effect one day later, but only when dissociative symptoms are mild to moderate. For every one-point increase on a dissociation scale up to 15 points, depression scores improved by an average of 0.5 points after 24 hours. This relationship was not observed at 72 hours or 7 days after infusion. The study was not originally designed to test this relationship, so confounding factors were not controlled, and the finding should be considered suggestive rather than definitive.

DOI: 10.47626/2237-6089-2022-0593 Full text Esketamine Treatment-resistant depression Major depressive disorder Dissociation